GlassScriptPhysician profile
Alan V Jones
NPI 1982640710
$6,003.42
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $371 · 2021: $1,347 · 2022: $1,717 · 2023: $1,158 · 2024: $24.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.63 | 2019-2023 | |
| Lilly USA, LLC | $600.81 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $578.82 | 2019-2023 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $514.91 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $448.78 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $417.09 | 2019-2023 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $384.34 | 2019-2023 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $330.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $201.04 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $121.01 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.23 | 2022 | |
| Astellas Pharma US INC | $116.69 | 2019-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $76.83 | 2019 | |
| Exact Sciences Corporation | $74.87 | 2023 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.